479 Jessie St.
San Francisco, CA 94103
SyntheX is a therapeutics company that disrupts cellular communication pathways to target proteins that are inaccessible via canonical screening technologies. We use a proprietary drug design approach and our in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs) – in a fast, efficient, and highly specific manner.
We take advantage of synthetic lethality to develop compounds that target particular “Achilles’ heel” PPI in specific pathologies. We are currently developing inhibitors for a series of specific and previously undruggable targets. Our lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, effectively mimicking a BRCA2 mutation and downregulating recombination.
Cancer; Genetic Diseases
Clinical Development Stage